Cantor Fitzgerald has initiated coverage on Monopar Therapeutics (MNPR, Financial) with an "Overweight" rating. The announcement was made by analyst Kristen Kluska on July 7, 2025. This rating suggests a favorable outlook for the stock, indicating that the firm believes MNPR will outperform the average return of the stocks in the analyst's coverage universe over the next 12 months.
The firm has set a price target of $74.00 USD for Monopar Therapeutics (MNPR, Financial), as announced by the analyst. This price target reflects the firm's assessment of MNPR's future market potential and growth prospects.
Monopar Therapeutics (MNPR, Financial) is a biopharmaceutical company that continues to be a focus for investors, particularly following Cantor Fitzgerald's latest analysis. With the newly initiated coverage and the "Overweight" rating, investors may keep a closer watch on the developments around MNPR in the upcoming months.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Monopar Therapeutics Inc (MNPR, Financial) is $61.25 with a high estimate of $76.00 and a low estimate of $40.00. The average target implies an upside of 64.65% from the current price of $37.20. More detailed estimate data can be found on the Monopar Therapeutics Inc (MNPR) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Monopar Therapeutics Inc's (MNPR, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
